MedTrace Logo

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-02-05

Study results available
· View outcomes & findings →

Summary

The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BI 1744 (Olodaterol) Low Dose

BI1744 Respimat low dose once daily and placebo Foradil

DRUG

BI 1744 (Olodaterol) Medium Dose

BI1744 Respimat medium dose once daily and placebo Foradil

DRUG

Placebo

Placebo Respimat once daily and placebo Foradil

DRUG

Foradil

12 mcg twice daily and placebo Respimat

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00932646 on ClinicalTrials.gov